Paper Details

  1. Home
  2. Paper Details

Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis.

Author: ChoiJong Wook, KoSoon Young, SeoHee Yeon, SeoMyeong-Sook, YoonSun-Young

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the safety and outcome of administering sofosbuvir plus low-dose ribavirin in hemodialysis patients with hepatitis C virus genotype 2 infection. The findings suggest that full-dose sofosbuvir plus low-dose ribavirin is a safe and effective treatment option for HCV genotype 2 infection in this patient population.
Paper Details　
Original Abstract of the Article :
New direct-acting antivirals have shown surprising success in the treatment of hepatitis C, not only in the general population, but also in difficult-to-treat cohorts. However, there is still limited data regarding direct-acting antivirals, including sofosbuvir (SOF), in the context of hemodialysis....See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214360/

データ提供：米国国立医学図書館（NLM）

Sofosbuvir and Ribavirin: A New Hope for Hepatitis C in Hemodialysis Patients

Hepatitis C is a serious liver disease that can lead to significant health complications. New direct-acting antivirals (DAAs) have shown promising results in treating hepatitis C, but data regarding their use in hemodialysis patients is limited. This study investigates the safety and effectiveness of a combination therapy of sofosbuvir and ribavirin in hemodialysis patients with hepatitis C genotype 2 infection.

Sofosbuvir and Ribavirin: A Promising Combination Therapy

The study found that full-dose sofosbuvir plus low-dose ribavirin was a safe and effective treatment option for hepatitis C genotype 2-infected patients on hemodialysis. This finding opens up new avenues for treating hepatitis C in this difficult-to-treat population. The authors conducted a clinical trial to assess the safety and efficacy of this combination therapy, providing valuable data for clinicians managing hepatitis C in hemodialysis patients.

Navigating the Desert of Hepatitis C: A Camel's Perspective

Just as a camel must adapt to the challenging desert environment, hepatitis C patients face a difficult journey with their disease. This study brings hope to hemodialysis patients with hepatitis C, demonstrating the potential of this combination therapy to offer a safe and effective treatment option.

Dr.Camel's Conclusion

This study provides encouraging results for the treatment of hepatitis C in hemodialysis patients. The combination therapy of sofosbuvir and ribavirin appears to be a safe and effective option, offering hope for improved outcomes in this vulnerable population.

Date :
  1. Date Completed 2021-06-24
  2. Date Revised 2021-06-24
Further Info :

Pubmed ID

31064176

DOI: Digital Object Identifier

PMC7214360

Related Literature

Article Analysis
・Side Effects of sofosbuvir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.